Combination fibrinolytic therapy in the treatment of chronic septic pleuropneumonia in a Thoroughbred gelding.

This research article presents a case study on the treatment of chronic pleuropneumonia in a 3-year-old Thoroughbred horse using a combination of fibrinolytic drugs – tenecteplase and alphadornase. The treatment resulted in a reduction in fibrin deposition and fluid accumulation in the horse’s pleural cavities, suggesting that fibrinolytic therapy might be effective for similar diseases in horses.

Introduction

• The research focuses on the treatment of chronic pleuropneumonia- a long-lasting inflammatory lung disease often caused by bacterial infection- in a 3-year-old Thoroughbred gelding, a castrated male horse specifically bred for racing.
• There has been an increased interest in exploring alternative or adjunctive treatments for managing such diseases in horses.

Methodology

• The study used a combination of two types of fibrinolytic drugs – recombinant tissue plasminogen activator (tenecteplase) and recombinant deoxyribonucleic acidase (alphadornase).
• These drugs were infused directly into the horse’s pleural cavity – space between the two pleurae of the lungs- in the early stages of treatment.
• Fibrinolytic drugs are typically used to dissolve blood clots by breaking down fibrin, a protein that holds the clots together.

Findings and Conclusion

• Following the therapy, the authors observed a subjective reduction in the amount of fibrin deposition- accumulation of fibrin on the tissue surfaces- in the horse’s pleural cavity.
• There was also less fluid accumulation within the pleural cavities post-treatment.
• The authors propose that fibrinolytic therapy may hence be a useful adjunctive treatment for intrapleural diseases such as pleuropneumonia in horses.
• The report provides new insights about the potential application of fibrinolytic therapy in veterinary medicine, particularly in equine species.